Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Mack

Showing results (291-300 of 444) with videos related to

Pageof 45
Sort By:
Kidney Cancer (Clifton, Va.)|November 26, 2019
Everolimus Exposure as a Predictor of Toxicity in Renal Cell Cancer Patients in the Adjuvant Setting: Results of a Pharmacokinetic Analysis for SWOG S0931 (EVEREST), a Phase III Study (NCT01120249)Timothy W Synold, Melissa Plets, Catherine M Tangen, et al.
Nature|August 23, 2019
Increasing wildfires threaten historic carbon sink of boreal forest soilsXanthe J Walker, Jennifer L Baltzer, Steven G Cumming, et al.
Nature|May 23, 2000
Consequences of changing biodiversityF S Chapin, E S Zavaleta, V T Eviner, et al.
Clinical Lung Cancer|June 18, 2021
Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878)Jonathan W Riess, Karen L Reckamp, Paul Frankel, et al.
BMC Cancer|April 22, 2021
A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancersKristin L Ayers, Meng Ma, Gaspard Debussche, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 9, 2013
Histology-related associations of ERCC1, RRM1, and TS biomarkers in patients with non-small-cell lung cancer: implications for therapyMartin K H Maus, Philip C Mack, Stephanie H Astrow, et al.
Molecular Cancer Research : MCR|April 3, 2020
Targeting NAD<sup>+</sup> Biosynthesis Overcomes Panobinostat and Bortezomib-Induced Malignant Glioma ResistanceEsther P Jane, Daniel R Premkumar, Swetha Thambireddy, et al.
Brain Pathology (Zurich, Switzerland)|May 10, 2012
Nestin expression identifies ependymoma patients with poor outcomeTill Milde, Thomas Hielscher, Hendrik Witt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2010
Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342Roy S Herbst, Karen Kelly, Kari Chansky, et al.
Clinical Lung Cancer|January 29, 2011
Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trialPrimo N Lara, Jeff Longmate, Karen Reckamp, et al.
Pageof 45

Showing results (291-300 of 444) with videos related to

Sort By:
Pageof 45
Kidney Cancer (Clifton, Va.)|November 26, 2019
Everolimus Exposure as a Predictor of Toxicity in Renal Cell Cancer Patients in the Adjuvant Setting: Results of a Pharmacokinetic Analysis for SWOG S0931 (EVEREST), a Phase III Study (NCT01120249)Timothy W Synold, Melissa Plets, Catherine M Tangen, et al.
Nature|August 23, 2019
Increasing wildfires threaten historic carbon sink of boreal forest soilsXanthe J Walker, Jennifer L Baltzer, Steven G Cumming, et al.
Nature|May 23, 2000
Consequences of changing biodiversityF S Chapin, E S Zavaleta, V T Eviner, et al.
Clinical Lung Cancer|June 18, 2021
Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878)Jonathan W Riess, Karen L Reckamp, Paul Frankel, et al.
BMC Cancer|April 22, 2021
A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancersKristin L Ayers, Meng Ma, Gaspard Debussche, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 9, 2013
Histology-related associations of ERCC1, RRM1, and TS biomarkers in patients with non-small-cell lung cancer: implications for therapyMartin K H Maus, Philip C Mack, Stephanie H Astrow, et al.
Molecular Cancer Research : MCR|April 3, 2020
Targeting NAD<sup>+</sup> Biosynthesis Overcomes Panobinostat and Bortezomib-Induced Malignant Glioma ResistanceEsther P Jane, Daniel R Premkumar, Swetha Thambireddy, et al.
Brain Pathology (Zurich, Switzerland)|May 10, 2012
Nestin expression identifies ependymoma patients with poor outcomeTill Milde, Thomas Hielscher, Hendrik Witt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2010
Phase II selection design trial of concurrent chemotherapy and cetuximab versus chemotherapy followed by cetuximab in advanced-stage non-small-cell lung cancer: Southwest Oncology Group study S0342Roy S Herbst, Karen Kelly, Kari Chansky, et al.
Clinical Lung Cancer|January 29, 2011
Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trialPrimo N Lara, Jeff Longmate, Karen Reckamp, et al.
Pageof 45